Jennifer Trottman, MD
Hematology & Oncology · Tulsa, OKNPI 1457393696
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,142 of the $3,660 with a category attached, or 85.8%. It is spread thinly across 39 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations.
Across 181 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$527
- Daiichi Sankyo Inc.$513
- Lilly USA, LLC$273
- Pfizer$265
- AstraZeneca$241
- Johnson & Johnson$142
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,14286%
- Education$51814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 33 | $527 |
| Daiichi Sankyo Inc. | 25 | $513 |
| Lilly USA, LLC | 9 | $273 |
| Pfizer | 13 | $265 |
| AstraZeneca(2 entities) | 13 | $241 |
| Johnson & Johnson | 8 | $142 |
| E.r. Squibb & Sons, L.L.C. | 2 | $141 |
| Seagen Inc. | 3 | $129 |
| AbbVie | 7 | $127 |
| Astellas Pharma US Inc | 2 | $120 |
| Sanofi | 6 | $118 |
| Taiho Oncology, Inc. | 6 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $93 |
| Dendreon Pharmaceuticals LLC | 3 | $88 |
| AVEO Pharmaceuticals, Inc. | 4 | $82 |
| Amgen | 5 | $71 |
| Genmab U.S., Inc. | 3 | $67 |
| Array Biopharma Inc | 3 | $64 |
| Genentech USA, Inc. | 3 | $53 |
| Incyte Corporation | 3 | $45 |
| Merck | 3 | $44 |
| Jazz Pharmaceuticals Inc. | 2 | $41 |
| Bayer | 1 | $29 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $29 |
| Ipsen Biopharmaceuticals, Inc | 2 | $29 |
| Tersera Therapeutics LLC | 2 | $26 |
| Myovant Sciences Inc. | 1 | $24 |
| Eisai Inc. | 1 | $21 |
| Sobi, Inc | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $16 |
| Fortovia Therapeutics, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Gilead | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Geron Corporation | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,660 in reported general payments places this provider in the 65th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 15 | $47,704 |
| EliquisApixaban | 53 | $35,312 |
| Xtampza ErOxycodone Myristate | 12 | $13,575 |
| XareltoRivaroxaban | 21 | $12,278 |
| Hydroxyurea | 35 | $902 |
| Letrozole | 17 | $879 |
| Oxycodone Hcl | 19 | $639 |
| Warfarin Sodium | 26 | $557 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $437 |
| Bicalutamide | 24 | $356 |
| Prochlorperazine Maleate | 34 | $343 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $334 |
| Gabapentin | 27 | $322 |
| Acyclovir | 17 | $319 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $265 | $35,31253 claims |
| Johnson & JohnsonXarelto | $142 | $12,27821 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $12 | $31917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Tulsa
- Caleb ScheckelTulsa$159K
- Hassan KaleemTulsa$137K
- Scott ColeTulsa$20K
- Supriya KoyaTulsa$7K
- Venkata VosuriTulsa$6K
- Kevin WeibelTulsa$5K
- Ali MoussaTulsa$5K
- Paul El TombTulsa$4K
- Muhammad JanjuaTulsa$4K
- Lehi VangTulsa$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.